References
- Nagata S., Goldstein P. The Fas death factor. Science 1995; 267: 1449–1456
- Kayagaki N., Kawasaki A., Ebata T., Ohmoto H., Ikeda S., Inoue S., Yoshino K., Okumura K., Yagita H. Metalloproteinase-mediated release of human Fas ligand. Journal of Experimental Medicine 1995; 182: 1777–1783
- Tanaka M., Suda T., Haze K., Nakamura N., Sato K., Kimura F., Motoyoshi K., Mizuki M., Tagawa S., Ohga S., Hatake K., Drummond A. H., Nagata S. Fas ligand in human serum. Nature Medicine 1996; 2: 317–322
- Sato K., Kimura F., Nakamura Y., Murakami H., Yoshida M., Tanaka M., Nagata S., Kanatani Y., Wakimoto N., Nagata N., Motoyoshi K. An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand. British Journal of Haematology 1996; 94: 379–382
- Kanda Y., Tanaka Y., Shirakawa K., Yatomi T., Nakamura N., Kami M., Saito T., Izutsu K., Asai T., Yuji K., Ogawa S., Honda H., Mitani K., Chiba S., Yazaki Y., Hirai H. Increased soluble Fas-Iigand in sera of bone marrow transplant recipients with acute graft-versus-host disease. Bone Marrow Transplantation 1998; 22: 751–754
- Attal M., Harousseau J. L., Stoppa A. M., Sotto J. J., Fuzibet J. G., Rossi J. F., Casassus P., Maisonneuve H., Facon T., Ifrah N., Payen C., Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New England Journal of Medicine 1996; 335: 91–97
- Villunger A., Egle A., Marschitz I., Kos M., Bock G., Ludwig H., Geley S., Kofler R., Greil R. Constitutive expression of Fas (Apo-l/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor-induced suppression of immune surveillance. Blood 1997; 90: 12–20
- Xerri L., Devilard E., Hassoun J., Haddad P., Birg F. Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas-mediated apoptosis. Leukemia 1997; 11: 1868–1877
- Kanda Y., Chiba S., Tanaka Y., Kami M., Saito T., Izutsu K., Asai T., Yuji K., Ogawa S., Honda H., Mitani K., Usuki K., Urabe A., Shirakawa K., Yatomi T., Nakamura N., Yazaki Y., Hirai H. Increased serum soluble Fas ligand associated with recurrent B-cell non-Hodgkin's lymphoma after autologous perioheral blood stem cell transplantation. Leukemia & Lymphoma 1999; 34: 625–628
- Tanaka M., Itai T., Adachi M., Nagata S. Down-regulation of Fas ligand by shedding. Nature Medicine 1998; 4: 31–36
- Dimopoulos M. A., Barlogie B., Smith T. L., Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Annals of Internal Medicine 1991; 115: 931–935
- Durie B. G., Stock-Novack D., Salmon S. E., Finley P., Beckord J., Crowley J., Coltman C. A. Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood 1990; 75: 823–830